Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285672 | 0.86 | GRM5 (0.42) | GRM5OGA | |
| SCHEMBL5090735 | 0.84 | GRM5 (0.43) | GRM5ACACBGPR183KCNH2 | |
| SCHEMBL4536276 | 0.80 | GRM5 (0.40) | GRM5OGA | |
| Hydrochloric Acid SCHEMBL5798994 | 0.77 | GRM5 (0.52) | GRM5 | |
| SCHEMBL28811006 | 0.76 | GRM5 (0.47) | GRM5 | |
| SCHEMBL8675743 | 0.76 | GRM5 (0.49) | GRM5 | |
| SCHEMBL2290995 | 0.74 | GRM5 (0.44) | GRM5KCNH2 | |
| SCHEMBL2892482 | 0.73 | GRM5 (0.43) | GRM5KCNH2 | |
| SCHEMBL4047546 | 0.70 | GRM5 (0.60) | GRM5 | |
| SCHEMBL4053802 | 0.70 | GRM5 (0.43) | GRM5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ERIKSSON ANDERS | 2009-12-03 | — | — | US | disclosed |
| EP-1732903-B1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| CN-1960979-A | Triazolone derivatives as MMP inhibitors for the treatment of asthma and copd | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | MMP9, MMP3, MMP25 | GRM5 2004/4885OGA 4520/4885ACACB 4257/4885 |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | MMP3, MMP9, MMP25 | GRM5 1923/4885OGA 4471/4885ACACB 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.